reports
Prana Commences Research Collaboration with Takeda for the Treatment o...
MELBOURNE, Australia & SAN FRANCISCO--(BUSINESS WIRE)-- Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced a research collaboration with Takeda Pharmaceuticals International, Inc. to study the ability of Prana’s investigational movement disorders compound, PBT434, to slow or prevent neurodegeneration of the gastrointestinal system. One of the important non-motor features of Parkinson’s disease is often the early presentation of severe and disabling impairment of gastrointestinal function. Parkinson’s disease is ch...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
New Data from Reach2HD Trial Presented at American Neurological Associ...
MELBOURNE, Australia--(BUSINESS WIRE)-- Prana Biotechnology Ltd (ASX:PBT/NASDAQ:PRAN) is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association (ANA) Annual Meeting in Baltimore, United States. Previously it has been reported that executive function as measured by the Trail Making Test Part B (TMTB) was significantly improved in the Reach2HD trial2. Moreover, as previously announced at the M...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.